Evidence map›Paper›PMID 25605921›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2015

Selective inactivation of USP18 isopeptidase activity in vivo enhances ISG15 conjugation and viral resistance.

Lars Ketscher, Ronny Hannß, David J Morales, Anja Basters, Susana Guerra, Tobias Goldmann, Annika Hausmann, Marco Prinz, Ronald Naumann, Andrew Pekosz and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 127 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. USP16 is an ISG15 cross-reactive deubiquitinase that targets pro-ISG15 and ISGylated proteins involved in metabolism.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 3 countries.

Lars KetscherInstitute of Neuropathology, University of Freiburg, 79106 Freiburg, Germany; Faculty of Biology, University of Freiburg, 79104 Freiburg, Germany;
Ronny HannßDepartment of General, Visceral, Vascular and Thoracic Surgery, Division of Molecular Biology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany; Fachbereich Biologie, Chemie, Pharmazie, Free University Berlin, 14195 Berlin, Germany;
David J MoralesDepartment of Medicine and Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110;
Anja BastersInstitute of Neuropathology, University of Freiburg, 79106 Freiburg, Germany; Faculty of Biology, University of Freiburg, 79104 Freiburg, Germany;
Susana GuerraDepartment of Preventive Medicine, Public Health and Microbiology, Universidad Autónoma Madrid, 28029 Madrid, Spain;
Tobias GoldmannInstitute of Neuropathology, University of Freiburg, 79106 Freiburg, Germany;
Annika HausmannInstitute of Neuropathology, University of Freiburg, 79106 Freiburg, Germany;
Marco PrinzInstitute of Neuropathology, University of Freiburg, 79106 Freiburg, Germany; Centre of Biological Signalling Studies (BIOSS), University of Freiburg, 79106 Freiburg, Germany;
Ronald NaumannMax Planck Institute of Molecular Cell Biology and Genetics, Transgenic Core Facility, 01307 Dresden, Germany;
Andrew PekoszW. Harry Feinstone Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205;
Olaf UtermöhlenInstitute for Medical Microbiology, Immunology and Hygiene, Medical Center, University of Cologne, 50935 Cologne, Germany; and Center for Molecular Medicine Cologne, University of Cologne, 50931 Cologne, Germany.
Deborah J LenschowDepartment of Medicine and Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110;
Klaus-Peter KnobelochInstitute of Neuropathology, University of Freiburg, 79106 Freiburg, Germany; klaus-peter.knobeloch@uniklinik-freiburg.de.
University of Freiburg · DEWashington University in St. Louis · USFreie Universität Berlin · DEJohns Hopkins University · USMax Planck Institute of Molecular Cell Biology and Genetics · DEUniversidad Autónoma de Madrid · ESUniversity of Cologne · DE

Funding

TRAINING PROGRAM IN CELLULAR AND MOLECULAR BIOLOGYT32GM007067 · NIGMS · WASHINGTON UNIVERSITY · PI TRUE-KROB, HEATHER L · 1985 to 2020
$20.4M
Viral Discovery in Rheumatoid ArthritisP30AR048335 · NIAMS · WASHINGTON UNIVERSITY · PI WEIHL, CONRAD C · 2001 to 2015
$8.9M
TRAINING IN THE IMMUNOLOGY OF RHEUMATIC DISEASEST32AR007279 · NIAMS · WASHINGTON UNIVERSITY · PI Megan Anne Cooper, Deborah J Lenschow · 1986 to 2026
$6.0M
REGULATION OF INFLUENZA VIRUS INFECTION BY ISG15R01AI080672 · NIAID · WASHINGTON UNIVERSITY · PI LENSCHOW, DEBORAH J · 2009 to 2021
$2.9M
NIAID NIH HHS R01 AI080672NIAMS NIH HHS P30 AR048335NIAMS NIH HHS P30AR048335NIAMS NIH HHS T32 AR007279NIGMS NIH HHS GM 007067NIGMS NIH HHS T32 GM007067
6 · The paper itself

Abstract

Protein modification by the ubiquitin-like protein ISG15 is an interferon (IFN) effector system, which plays a major role in antiviral defense. ISG15 modification is counteracted by the isopeptidase USP18, a major negative regulator of IFN signaling, which was also shown to exert its regulatory function in an isopeptidase-independent manner. To dissect enzymatic and nonenzymatic functions of USP18 in vivo, we generated knock-in mice (USP18(C61A/C61A)) expressing enzymatically inactive USP18. USP18(C61A/C61A) mice displayed increased levels of ISG15 conjugates, validating that USP18 is a major ISG15 isopeptidase in vivo. Unlike USP18(-/-) mice, USP18(C61A/C61A) animals did not exhibit morphological abnormalities, fatal IFN hypersensitivity, or increased lethality, clearly showing that major USP18 functions are unrelated to its protease activity. Strikingly, elevated ISGylation in USP18(C61A/C61A) mice was accompanied by increased viral resistance against vaccinia virus and influenza B virus infections. Enhanced resistance upon influenza B infection in USP18(C61A/C61A) mice was completely reversed in USP18(C61A/C61A) mice, which additionally lack ISG15, providing evidence that the observed reduction in viral titers is ISG15 dependent. These results suggest that increasing ISGylation by specific inhibition of USP18 protease activity could constitute a promising antiviral strategy with only a minimal risk of severe adverse effects.

Indexed as

Drug Resistance, ViralAnimalsAntiviral AgentsCells, CulturedCytokinesInfluenza B virusMiceMice, Inbred C57BLMice, TransgenicUbiquitinsUbiquitin ThiolesteraseAntiviral AgentsCytokinesG1p2 protein, mouseUbiquitinsUbiquitin ThiolesteraseUsp18 protein, mouseinfluenzainterferonISG15ubiquitin isopeptidaseUBP43

Identifiers

PMID25605921
PMCPMC4321242
OpenAlexW1976290862

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.